PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1743376
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1743376
Shingles Vaccine Market Growth, Size, Trends Analysis - By Product, By Vaccine Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Shingles Vaccine Market Introduction and Overview
According to SPER market research, 'Global Shingles Vaccine Market Size- By Product, By Vaccine Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Shingles Vaccine Market is predicted to reach 20.9 billion by 2034 with a CAGR of 15.58%.
The shingles vaccine is a prophylactic vaccination intended to guard against shingles, a painful rash brought on by the varicella-zoster virus (VZV), which is also the virus that triggers chickenpox. Postherpetic neuralgia (PHN) and other shingles consequences are less likely to occur when it strengthens the immune system's reaction. Due to an increased risk of shingles with age, the vaccine is mostly advised for older persons. The more modern recombinant vaccination (Shingrix), which is very effective, and the older live attenuated vaccine (Zostavax), which is less widely used, are the two primary varieties.
Restraints: The high cost of the shingles vaccine restricts accessibility, particularly in low-income areas, and is one of the market's many obstacles. Adoption is further hampered by misunderstandings and a lack of knowledge on shingles and vaccination. Issues with the supply chain, such as complicated distribution and storage, impact availability. There is still worry about vaccination reluctance brought on by mistrust of immunization programs and fear of adverse consequences. The launch of novel vaccines is delayed by regulatory obstacles and drawn-out approval procedures.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Product, By Vaccine Type
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
GlaxoSmithKline plc., Pfizer Inc., Merck & Co., Inc., CanSinoBIO, Vaccitech, Green Cross Corp, Geneone Life Science, SK Bioscience.
Global Shingles Vaccine Market Segmentation:
By Product: Based on the Product, Global Shingles Vaccine Market issegmented as; Shingrix, Zostavax, SKYZoster.
By Vaccine Type: Based on the Vaccine Type, GlobalShingles Vaccine Market is segmented as; Recombinant Vaccine, Live AttenuatedVaccine.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East& Africa.
Table of Contents
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER's internal database
2.1.4. Premium insight from KOL's
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER's Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Shingles Vaccine Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Shingles Vaccine Market
7. Global Shingles Vaccine Market, By Product 2021-2034 (USD Million)
7.1. Shingrix
7.2. Zostavax
7.3. SKYZoster
8. Global Shingles Vaccine Market, By Vaccine Type 2021-2034 (USD Million)
8.1. Recombinant Vaccine
8.2. Live Attenuated Vaccine
9. Global Shingles Vaccine Market, 2021-2034 (USD Million)
9.1. Global Shingles Vaccine Market Size and Market Share
10. Global Shingles Vaccine Market, By Region, 2021-2034 (USD Million)
.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
1.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. BioNTech SE
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. CanSinoBIO
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
1.3. CanSinoBIO
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Geneone Life Science
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. GlaxoSmithKline plc.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Green Cross Corp
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
.7. Merck & Co., Inc.
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Pfizer Inc.
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. SK Bioscience
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Vaccitech
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
